POM121 transmembrane nucleoporin like 2Genealiases: POM121-L · POM121L
Q-omics provides the consensus-scored POM121L2 profile across patient tissues and cancer cell-line models. POM121L2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, POM121L2 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, POM121L2 RNA expression shows 8,052 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight ESCA, KICH, and LIHC as cancer lineages where POM121L2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POM121L2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POM121L2 survival associations across molecular data types. POM121L2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POM121L2 RNA expression–survival associations across cancer types. High POM121L2 expression shows unfavorable associations in ESCA, KIRP, LUAD and THCA, but favorable associations in MESO and OV. The ESCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ESCA as the clearest survival context for POM121L2 RNA expression.
This table summarizes POM121L2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for POM121L2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POM121L2 shows lower tumor expression in KICH, THCA and COAD and higher tumor expression in BLCA, LUAD and LUSC. The KICH box plot shows higher POM121L2 RNA expression in normal versus tumor tissue (log2 FC = −0.045, t-test p < 0.001).
This table shows molecular features associated with POM121L2 in patient tissues and cancer cell lines. In patient samples, POM121L2 shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set. In cancer cell lines, POM121L2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
